Axa
VIR icon

Axa’s Vir Biotechnology VIR Stock Holding History

Axa’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,400
Closed -$219K – 1169
2023
Q1 		$219K Sell
9,400
-71,800
-88% -$1.84M ﹤0.01% 1064
2022
Q4 		$2.06M Buy
81,200
+52,700
+185% +$1.29M 0.01% 774
2022
Q3 		$549K Buy
+28,500
New +$725K ﹤0.01% 948
2022
Q2 		– Sell
-13,400
Closed -$345K – 1226
2022
Q1 		$345K Buy
+13,400
New +$397K ﹤0.01% 1089

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Axa's VIR Position: Q2 2023 in Review

Axa sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 9,400 shares — an estimated $219K sold.

Axa first reported a position in VIR in Q1 2022 and held it in 4 quarters. The position peaked at $2.06M in Q4 2022. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

  • Axa reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Axa sold 9,400 Vir Biotechnology shares in Q2 2023, an estimated $219K.
  • Axa first reported a position in Vir Biotechnology in Q1 2022 and held it in 4 quarters.
  • Axa's Vir Biotechnology position peaked at $2.06M in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.